BiotechTube

Durysta, Bimatoprost Intracameral Implant 10 µg

ApprovedRecruiting
0 views this week 0 watching⚡ Active
Interest: 50/100
50
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
✓
Phase 3
5
Approved
Indication / Disease

Glaucoma

Conditions

Glaucoma, Open-Angle Glaucoma, Ocular Hypertension, Glaucoma Suspect

Trial Timeline

Feb 9, 2026 → Jan 31, 2028

NCT ID
NCT07217678

About Durysta, Bimatoprost Intracameral Implant 10 µg

Durysta, Bimatoprost Intracameral Implant 10 µg is a approved stage product being developed by AbbVie for Glaucoma. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07217678. Target conditions include Glaucoma, Open-Angle Glaucoma, Ocular Hypertension.

What happened to similar drugs?

18 of 20 similar drugs in Glaucoma were approved

Approved (18) Terminated (3) Active (1)
✅Latanoprost plus adjunctive glaucoma medicationSight SciencesApproved
✅Eybelis ophthalmic solution 0.002%Santen PharmaceuticalApproved
✅Cosopt (combination eyedrop of dorzolamide and timolol)MerckApproved
✅Brinzolamide 1%/Timolol maleate 0.5% fixed combination ophthalmic suspension + Dorzolamide hydrochloride 1%/Timolol maleate 0.5% ophthalmic solution + Subject's habitual PGA monotherapyNovartisApproved
✅brinzolamide 1%/brimonidine 0.2% fixed combination + Placebo + travoprost 0.004% ophthalmic solutionNovartisApproved
✅Netarsudil ophthalmic solution 0.02% + Artificial tearsNovartisApproved
✅Xalatan + Travatan ZPfizerApproved

Hype Score Breakdown

Clinical
20
Activity
15
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT07217678ApprovedRecruiting

Competing Products

20 competing products in Glaucoma

See all competitors
ProductCompanyStageHype Score
Test - Bimatoprost 0.01% Ophthalmic Solution + Reference - LUMIGAN® (Bimatoprost 0.01% Ophthalmic Solution)Mankind PharmaPhase 3
40
Latanoprost plus adjunctive glaucoma medicationSight SciencesApproved
25
SBI-100 Ophthalmic Emulsion, 0.5% + SBI-100 Ophthalmic Emulsion, 1.0% + SBI-100 Ophthalmic Emulsion, PlaceboSkye BiosciencePhase 2
25
SDP-133 + LumiganSun PharmaceuticalPhase 3
32
Brinzolamide ophthalmic suspension + Azopt®Sun PharmaceuticalPhase 3
40
Eybelis ophthalmic solution 0.002%Santen PharmaceuticalApproved
39
STN1012600 ophthalmic solution 0.002% + STN1012600 ophthalmic solution 0.002% + STN1012600 ophthalmic solution 0.002% and Timolol ophthalmic solution 0.5%Santen PharmaceuticalPhase 3
40
Latanoprost + tafluprostSanten PharmaceuticalPre-clinical
26
DE-117B Eye Drops + LatanoprostSanten PharmaceuticalPhase 3
47
DE-104 ophthalmic solution + DE-104 vehicleSanten PharmaceuticalPhase 2
35
DE-111 ophthalmic solution + Tafluprost ophthalmic solution 0.0015% + Concomitant use of tafluprost ophthalmic solution 0.0015% plus timolol ophthalmic solution 0.5%Santen PharmaceuticalPhase 3
40
DE-111 ophthalmic solutionSanten PharmaceuticalPhase 3
40
DE-111 ophthalmic solution + Timolol ophthalmic solution 0.5% + Placebo ophthalmic solutionSanten PharmaceuticalPhase 3
40
DE-104 ophthalmic solution, low concentration + DE-104 ophthalmic solution, medium concentration + DE-104 ophthalmic solution, high concentration + DE-104 vehicleSanten PharmaceuticalPhase 2
35
DE-117 ophthalmic solution + Latanoprost ophthalmic solution 0.005%Santen PharmaceuticalPhase 3
40
STN1012600 ophthalmic solution 0.002% + Latanoprost ophthalmic solution 0.005%Santen PharmaceuticalPhase 3
40
DE-117 + Latanoprost ophthalmic solutionSanten PharmaceuticalPhase 3
40
DE-117 ophthalmic solution + Timolol ophthalmic solutionSanten PharmaceuticalPhase 3
40
A preservative-free, a clear, colorless sterile aqueous ophthalmic solution containing 0.015mg of tafluprost and 5.0mg of timolol in 1mL + A preservative-free, a clear, colorless sterile aqueous ophthalmic solution containing 0.015mg of tafluprost in 1mLSanten PharmaceuticalPhase 3
40
Placebo ophthalmic solution + DE-117 ophthalmic solution low + DE-117 ophthalmic solution high + Latanoprost ophthalmic solution 0.005%Santen PharmaceuticalPhase 2/3
38